Ondansetron hydrochloride is a Small Molecule owned by Adial Pharmaceuticals, and is involved in 4 clinical trials, of which 2 were completed, and 2 are planned.

Ondansetron (AD-04) acts as serotonin-3 (5-HT3) receptor antagonists. An imbalance between two chemical messengers in the brain, serotonin and dopamine, is believed to create a craving for alcohol. The 5-HT antagonists modulate some of the behavioral effects of alcohol and has an effect on other neurotransmitters like dopamine. The drug candidate by antagonizing the receptor, ameliorates the condition.

The revenue for Ondansetron hydrochloride is expected to reach a total of $993m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ondansetron hydrochloride NPV Report.

Ondansetron hydrochloride is currently owned by Adial Pharmaceuticals.

Ondansetron hydrochloride Overview

Ondansetron (AD-04) is under development for the treatment of alcohol use disorder. AD-04 is a formulation of ondansetron. It is administered through intravenous route. Ondansetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. It was also under development for the treatment of obesity, opioid use disorder/addiction and smoking cessation.

Adial Pharmaceuticals Overview

Adial Pharmaceuticals (Adial Pharma) is a clinical-stage biopharmaceutical company that develops therapeutic agents. The company focuses on developing genetically targeted, serotonin-3 receptor antagonist AD04, for the treatment of alcohol use disorder (AUD) and other addictive disorders such as gambling, opioid use disorder and obesity. It is also conducting the clinical phase of the ONWARD pivotal phase 3 clinical trial for the potential treatment of AUD by using AD04. In addition, the company through its subsidiary developing adenosine analogs for the treatment of cancer, diabetes, pain, asthma and other disorders. The company collaborates with universities and medical colleges to develop therapies. Adial Pharma is headquartered in Charlottesville, Virginia, the US.

The operating loss of the company was US$19.3 million in FY2021, compared to an operating loss of US$10.9 million in FY2020. The net loss of the company was US$19.4 million in FY2021, compared to a net loss of US$10.9 million in FY2020.

Quick View – Ondansetron hydrochloride

Report Segments
  • Innovator
Drug Name
  • Ondansetron hydrochloride
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Central Nervous System
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.